𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An open-label study of escitalopram (Lexapro®) for the treatment of ‘Depression of Alzheimer's disease’ (dAD)

✍ Scribed by V. Rao; J. R. Spiro; P. B. Rosenberg; H. B. Lee; A. Rosenblatt; C. G. Lyketsos

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
43 KB
Volume
21
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Depression is a frequent neuropsychiatric complication of Alzheimer's Disease.

Methods

This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8‐week, open‐label treatment study.

Conclusion

Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population. Copyright © 2006 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Extracorporeal photopheresis for the tre
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study
✍ Maria T. Abreu; Christian von Tirpitz; Robert Hardi; Martin Kaatz; Gert Van Assc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Background: Extracorporeal photopheresis (ecp) is effective in immune-mediated disorders. a prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ecp in patients with active crohn's disease (cd) who were refractory to or intolerant of immunosuppressants and/o

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo

Atomoxetine for the treatment of executi
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

Specific symptomatic changes following d
Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study
✍ Kenneth Rockwood; Sandra Black; Marc-Andre Bedard; Thang Tran; Isabelle Lussier 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB

## Abstract ## Background Standard measurement scales used in anti‐dementia trials may not capture symptomatic changes recognized by clinicians and caregivers. We studied a symptom checklist, completed separately by caregivers and by clinicians, to identify patterns of change associated with donep

Paroxetine in the treatment of depressed
Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study
✍ Chi-Un Pae; Yoo-Jin Kim; Wang-Youn Won; Hee-Je Kim; Seok Lee; Chang-Uk Lee; Soo- 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 1 views

## Abstract ## Objective The efficacy and tolerability of paroxetine in the treatment of depressive disorders is well known, however, its efficacy and safety for the treatment of depression in patients with cancer has been poorly studied. Therefore this study was aimed at evaluating the efficacy a